| ■ 영문 제목 : Global Hospital Infection Therapeutics Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR75007-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 2월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역 ■ 산업 분야 : 의료 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| Technavio사는 세계의 원내 감염 치료제 시장 규모가 2022년부터 2027년 사이에 3,106.6백만 달러에 이르며, 예측 기간 동안 연평균 4.98% 성장할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 원내 감염 치료제 시장에 대해 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 치료제별 (항생제, 항진균제, 항바이러스제) 분석, 종류별 (기도 감염, 수술 부위 감염, 혈류 감염, 위장 감염, 기타) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아 태평양, 기타 지역, 미국, 독일, 중국, 프랑스, 영국) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 Abbott Laboratories, AbbVie Inc., Achilles Therapeutics plc, AstraZeneca Plc, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson과 같은 등의 기업 정보를 포함하고 있습니다. ・개요 ・시장 현황 ・시장 규모 예측 ・과거 시장 규모 ・Five Force 분석 ・세계의 원내 감염 치료제 시장 규모 : 치료제별 - 항생제의 시장 규모 - 항진균제의 시장 규모 - 항바이러스제의 시장 규모 ・세계의 원내 감염 치료제 시장 규모 : 종류별 -기도 감염 치료제의 시장 규모 - 수술 부위 감염 치료제의 시장 규모 - 혈류 감염 치료제의 시장 규모 - 위장 감염 치료제의 시장 규모 - 기타 종류의 시장 규모 ・지역별 현황 - 북미의 원내 감염 치료제 시장 규모 - 유럽의 원내 감염 치료제 시장 규모 - 아시아 태평양의 원내 감염 치료제 시장 규모 - 기타 지역의 원내 감염 치료제 시장 규모 - 미국의 원내 감염 치료제 시장 규모 - 독일의 원내 감염 치료제 시장 규모 - 중국의 원내 감염 치료제 시장 규모 - 프랑스의 원내 감염 치료제 시장 규모 - 영국의 원내 감염 치료제 시장 규모 ・성장 요인/과제/동향 ・기업 현황 ・기업 분석 Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 원내 감염 치료제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 원내 감염 치료제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
글로벌 병원 감염 치료제 시장은 2023년부터 2027년까지 3106.6백만 달러 성장할 것으로 예상되며, 이 기간 동안 연평균 성장률(CAGR)은 4.98%에 이를 것으로 보입니다. 이 보고서는 병원 감염 치료제 시장에 대한 종합적인 분석을 제공하며, 시장 규모와 전망, 최신 동향 및 성장 요인, 도전 과제, 그리고 약 25개의 주요 공급업체에 대한 분석을 포함하고 있습니다. 현재 시장 상황에 대한 최신 분석과 함께, 증가하는 호흡기 질환의 발생 및 유병률, 고령 인구의 증가, 특수 약물 지정을 포함한 다양한 성장 요인이 시장을 주도하고 있습니다.
병원 감염 치료제 시장은 약물 클래스에 따라 항생제, 항진균제, 항바이러스제로 분류되며, 유형에 따라 호흡기 감염, 수술 부위 감염, 혈류 감염, 위장관 감염, 비뇨기 감염으로 세분화됩니다. 지역별로는 북미, 유럽, 아시아, 기타 지역(ROW)으로 나뉩니다. 이 연구에서는 병원 방문 증가가 향후 몇 년 동안 병원 감염 치료제 시장 성장의 주요 요인 중 하나로 식별되며, 개발도상국의 충족되지 않은 필요와 병원 내 감염 관리 위원회에 대한 수요 증가가 시장의 상당한 수요를 이끌 것으로 예상하고 있습니다.
Technavio는 여러 출처에서의 데이터 분석을 통해 시장의 상세한 그림을 제시하며, 병원 감염 치료제 시장의 크기, 전망, 산업 분석을 포함합니다. 이 보고서는 Abbott Laboratories, AbbVie Inc., Achilles Therapeutics plc, AstraZeneca Plc, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Spero Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc. 등 주요 공급업체에 대한 상세 분석을 제공합니다. 또한, 병원 감염 치료제 시장의 분석 보고서는 시장 성장에 영향을 미칠 향후 동향과 도전 과제에 대한 정보도 포함되어 있어 기업들이 향후 성장 기회를 전략적으로 활용할 수 있도록 돕습니다.
이 연구는 주요 산업 참여자들의 입력을 포함한 1차 및 2차 정보의 객관적인 조합을 사용하여 수행되었습니다. 보고서는 포괄적인 시장 및 공급업체 환경과 주요 공급업체 분석을 포함하고 있습니다. Technavio는 이익, 가격, 경쟁, 프로모션 등 주요 매개변수를 분석하여 시장의 다양한 측면을 제시하며, 주요 산업 영향력을 파악하는 데 도움을 줍니다. 제공된 데이터는 포괄적이고 신뢰할 수 있으며, 광범위한 연구 결과입니다. Technavio의 시장 조사 보고서는 완전한 경쟁 환경과 정성적 및 정량적 연구를 이용한 심층 공급업체 선택 방법론을 제공하여 정확한 시장 성장을 예측합니다.
■ 보고서 목차• 1 요약 • 3 시장 규모 • 4 과거 시장 규모 o 표 38: 항진균제 – 시장 규모 및 전망 2022-2027 (백만 달러) (백만 달러) (백만 달러) • 9 지역별 시장 현황 o 표 89: 기타 지역(ROW) 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) o 표 92: 기타 지역(ROW) 데이터 표 – 2022-2027년 전년 대비 성장률(%) o 표 117: 주요 위험이 사업에 미치는 영향 • 12 공급업체 분석 o 12.1 분석 대상 공급업체 o 표 125: 애브비 – 개요 o 표 138: 바이엘(Bayer AG) – 주요 뉴스 o 표 181: 비아트리스 – 개요 첨부 자료: 첨부 자료1: 요약 요약 – 시장 개요 차트 표 40: 항진균제 시장 현황 – 2022-2027년 전년 대비 성장률(%) 표 66: 위장관 감염 데이터 표 – 2022-2027년 전년 대비 성장률(%) 표 74: 2022-2027년 지역별 시장 점유율 데이터표(%) 첨부자료 142: 브리스톨 마이어스 스큅(Bristol Myers Squibb Co.) – 제품/서비스 첨부자료 152: 길리어드 사이언스(Gilead Sciences Inc.) – 주요 뉴스 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market by Geography o Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class o Exhibit 06: Executive Summary - Chart on Market Segmentation by Type o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global hospital infection therapeutics market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global hospital infection therapeutics market 2017 - 2021 ($ million) o 4.2 Drug Class Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million) o 4.3 Type Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Drug Class o 6.1 Market segments o Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%) o Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%) o 6.2 Comparison by Drug Class o Exhibit 32: Chart on Comparison by Drug Class o Exhibit 33: Data Table on Comparison by Drug Class o 6.3 Antibiotics drugs - Market size and forecast 2022-2027 o Exhibit 34: Chart on Antibiotics drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Antibiotics drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Antibiotics drugs - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Antibiotics drugs - Year-over-year growth 2022-2027 (%) o 6.4 Antifungal drugs - Market size and forecast 2022-2027 o Exhibit 38: Chart on Antifungal drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Antifungal drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Antifungal drugs - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Antifungal drugs - Year-over-year growth 2022-2027 (%) o 6.5 Antiviral drugs - Market size and forecast 2022-2027 o Exhibit 42: Chart on Antiviral drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 43: Data Table on Antiviral drugs - Market size and forecast 2022-2027 ($ million) o Exhibit 44: Chart on Antiviral drugs - Year-over-year growth 2022-2027 (%) o Exhibit 45: Data Table on Antiviral drugs - Year-over-year growth 2022-2027 (%) o 6.6 Market opportunity by Drug Class o Exhibit 46: Market opportunity by Drug Class ($ million) • 7 Market Segmentation by Type o 7.1 Market segments o Exhibit 47: Chart on Type - Market share 2022-2027 (%) o Exhibit 48: Data Table on Type - Market share 2022-2027 (%) o 7.2 Comparison by Type o Exhibit 49: Chart on Comparison by Type o Exhibit 50: Data Table on Comparison by Type o 7.3 Respiratory tract infections - Market size and forecast 2022-2027 o Exhibit 51: Chart on Respiratory tract infections - Market size and forecast 2022-2027 ($ million) o Exhibit 52: Data Table on Respiratory tract infections - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Chart on Respiratory tract infections - Year-over-year growth 2022-2027 (%) o Exhibit 54: Data Table on Respiratory tract infections - Year-over-year growth 2022-2027 (%) o 7.4 Surgical site infections - Market size and forecast 2022-2027 o Exhibit 55: Chart on Surgical site infections - Market size and forecast 2022-2027 ($ million) o Exhibit 56: Data Table on Surgical site infections - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Chart on Surgical site infections - Year-over-year growth 2022-2027 (%) o Exhibit 58: Data Table on Surgical site infections - Year-over-year growth 2022-2027 (%) o 7.5 Bloodstream infections - Market size and forecast 2022-2027 o Exhibit 59: Chart on Bloodstream infections - Market size and forecast 2022-2027 ($ million) o Exhibit 60: Data Table on Bloodstream infections - Market size and forecast 2022-2027 ($ million) o Exhibit 61: Chart on Bloodstream infections - Year-over-year growth 2022-2027 (%) o Exhibit 62: Data Table on Bloodstream infections - Year-over-year growth 2022-2027 (%) o 7.6 Gastrointestinal infections - Market size and forecast 2022-2027 o Exhibit 63: Chart on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million) o Exhibit 64: Data Table on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million) o Exhibit 65: Chart on Gastrointestinal infections - Year-over-year growth 2022-2027 (%) o Exhibit 66: Data Table on Gastrointestinal infections - Year-over-year growth 2022-2027 (%) o 7.7 Urinary tract infections - Market size and forecast 2022-2027 o Exhibit 67: Chart on Urinary tract infections - Market size and forecast 2022-2027 ($ million) o Exhibit 68: Data Table on Urinary tract infections - Market size and forecast 2022-2027 ($ million) o Exhibit 69: Chart on Urinary tract infections - Year-over-year growth 2022-2027 (%) o Exhibit 70: Data Table on Urinary tract infections - Year-over-year growth 2022-2027 (%) o 7.8 Market opportunity by Type o Exhibit 71: Market opportunity by Type ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 73: Chart on Market share by geography 2022-2027 (%) o Exhibit 74: Data Table on Market share by geography 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 75: Chart on Geographic comparison o Exhibit 76: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 Germany - Market size and forecast 2022-2027 o Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.9 China - Market size and forecast 2022-2027 o Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.10 France - Market size and forecast 2022-2027 o Exhibit 105: Chart on France - Market size and forecast 2022-2027 ($ million) o Exhibit 106: Data Table on France - Market size and forecast 2022-2027 ($ million) o Exhibit 107: Chart on France - Year-over-year growth 2022-2027 (%) o Exhibit 108: Data Table on France - Year-over-year growth 2022-2027 (%) o 9.11 UK - Market size and forecast 2022-2027 o Exhibit 109: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 110: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 111: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 112: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity by geography o Exhibit 113: Market opportunity by geography ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 114: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 115: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 116: Overview on factors of disruption o 11.4 Industry risks o Exhibit 117: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 118: Vendors covered o 12.2 Market positioning of vendors o Exhibit 119: Matrix on vendor position and classification o 12.3 Abbott Laboratories o Exhibit 120: Abbott Laboratories - Overview o Exhibit 121: Abbott Laboratories - Business segments o Exhibit 122: Abbott Laboratories - Key news o Exhibit 123: Abbott Laboratories - Key offerings o Exhibit 124: Abbott Laboratories - Segment focus o 12.4 AbbVie Inc. o Exhibit 125: AbbVie Inc. - Overview o Exhibit 126: AbbVie Inc. - Product / Service o Exhibit 127: AbbVie Inc. - Key news o Exhibit 128: AbbVie Inc. - Key offerings o 12.5 Achilles Therapeutics plc o Exhibit 129: Achilles Therapeutics plc - Overview o Exhibit 130: Achilles Therapeutics plc - Product / Service o Exhibit 131: Achilles Therapeutics plc - Key offerings o 12.6 AstraZeneca Plc o Exhibit 132: AstraZeneca Plc - Overview o Exhibit 133: AstraZeneca Plc - Product / Service o Exhibit 134: AstraZeneca Plc - Key news o Exhibit 135: AstraZeneca Plc - Key offerings o 12.7 Bayer AG o Exhibit 136: Bayer AG - Overview o Exhibit 137: Bayer AG - Business segments o Exhibit 138: Bayer AG - Key news o Exhibit 139: Bayer AG - Key offerings o Exhibit 140: Bayer AG - Segment focus o 12.8 Bristol Myers Squibb Co. o Exhibit 141: Bristol Myers Squibb Co. - Overview o Exhibit 142: Bristol Myers Squibb Co. - Product / Service o Exhibit 143: Bristol Myers Squibb Co. - Key news o Exhibit 144: Bristol Myers Squibb Co. - Key offerings o 12.9 F. Hoffmann La Roche Ltd. o Exhibit 145: F. Hoffmann La Roche Ltd. - Overview o Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments o Exhibit 147: F. Hoffmann La Roche Ltd. - Key news o Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings o Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus o 12.10 Gilead Sciences Inc. o Exhibit 150: Gilead Sciences Inc. - Overview o Exhibit 151: Gilead Sciences Inc. - Product / Service o Exhibit 152: Gilead Sciences Inc. - Key news o Exhibit 153: Gilead Sciences Inc. - Key offerings o 12.11 GlaxoSmithKline Plc o Exhibit 154: GlaxoSmithKline Plc - Overview o Exhibit 155: GlaxoSmithKline Plc - Business segments o Exhibit 156: GlaxoSmithKline Plc - Key offerings o Exhibit 157: GlaxoSmithKline Plc - Segment focus o 12.12 Johnson and Johnson o Exhibit 158: Johnson and Johnson - Overview o Exhibit 159: Johnson and Johnson - Business segments o Exhibit 160: Johnson and Johnson - Key news o Exhibit 161: Johnson and Johnson - Key offerings o Exhibit 162: Johnson and Johnson - Segment focus o 12.13 Merck and Co. Inc. o Exhibit 163: Merck and Co. Inc. - Overview o Exhibit 164: Merck and Co. Inc. - Business segments o Exhibit 165: Merck and Co. Inc. - Key news o Exhibit 166: Merck and Co. Inc. - Key offerings o Exhibit 167: Merck and Co. Inc. - Segment focus o 12.14 Novartis AG o Exhibit 168: Novartis AG - Overview o Exhibit 169: Novartis AG - Business segments o Exhibit 170: Novartis AG - Key offerings o Exhibit 171: Novartis AG - Segment focus o 12.15 Pfizer Inc. o Exhibit 172: Pfizer Inc. - Overview o Exhibit 173: Pfizer Inc. - Product / Service o Exhibit 174: Pfizer Inc. - Key news o Exhibit 175: Pfizer Inc. - Key offerings o 12.16 Sanofi SA o Exhibit 176: Sanofi SA - Overview o Exhibit 177: Sanofi SA - Business segments o Exhibit 178: Sanofi SA - Key news o Exhibit 179: Sanofi SA - Key offerings o Exhibit 180: Sanofi SA - Segment focus o 12.17 Viatris Inc. o Exhibit 181: Viatris Inc. - Overview o Exhibit 182: Viatris Inc. - Business segments o Exhibit 183: Viatris Inc. - Key offerings o Exhibit 184: Viatris Inc. - Segment focus • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 185: Inclusions checklist o Exhibit 186: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 187: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 188: Research methodology o Exhibit 189: Validation techniques employed for market sizing o Exhibit 190: Information sources o 13.5 List of abbreviations o Exhibit 191: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market by Geography Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class Exhibits6: Executive Summary - Chart on Market Segmentation by Type Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global hospital infection therapeutics market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Type Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Drug Class - Market share 2022-2027 (%) Exhibits31: Data Table on Drug Class - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Drug Class Exhibits33: Data Table on Comparison by Drug Class Exhibits34: Chart on Antibiotics drugs - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Antibiotics drugs - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Antibiotics drugs - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Antibiotics drugs - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Antifungal drugs - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Antifungal drugs - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Antifungal drugs - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Antifungal drugs - Year-over-year growth 2022-2027 (%) Exhibits42: Chart on Antiviral drugs - Market size and forecast 2022-2027 ($ million) Exhibits43: Data Table on Antiviral drugs - Market size and forecast 2022-2027 ($ million) Exhibits44: Chart on Antiviral drugs - Year-over-year growth 2022-2027 (%) Exhibits45: Data Table on Antiviral drugs - Year-over-year growth 2022-2027 (%) Exhibits46: Market opportunity by Drug Class ($ million) Exhibits47: Chart on Type - Market share 2022-2027 (%) Exhibits48: Data Table on Type - Market share 2022-2027 (%) Exhibits49: Chart on Comparison by Type Exhibits50: Data Table on Comparison by Type Exhibits51: Chart on Respiratory tract infections - Market size and forecast 2022-2027 ($ million) Exhibits52: Data Table on Respiratory tract infections - Market size and forecast 2022-2027 ($ million) Exhibits53: Chart on Respiratory tract infections - Year-over-year growth 2022-2027 (%) Exhibits54: Data Table on Respiratory tract infections - Year-over-year growth 2022-2027 (%) Exhibits55: Chart on Surgical site infections - Market size and forecast 2022-2027 ($ million) Exhibits56: Data Table on Surgical site infections - Market size and forecast 2022-2027 ($ million) Exhibits57: Chart on Surgical site infections - Year-over-year growth 2022-2027 (%) Exhibits58: Data Table on Surgical site infections - Year-over-year growth 2022-2027 (%) Exhibits59: Chart on Bloodstream infections - Market size and forecast 2022-2027 ($ million) Exhibits60: Data Table on Bloodstream infections - Market size and forecast 2022-2027 ($ million) Exhibits61: Chart on Bloodstream infections - Year-over-year growth 2022-2027 (%) Exhibits62: Data Table on Bloodstream infections - Year-over-year growth 2022-2027 (%) Exhibits63: Chart on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million) Exhibits64: Data Table on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million) Exhibits65: Chart on Gastrointestinal infections - Year-over-year growth 2022-2027 (%) Exhibits66: Data Table on Gastrointestinal infections - Year-over-year growth 2022-2027 (%) Exhibits67: Chart on Urinary tract infections - Market size and forecast 2022-2027 ($ million) Exhibits68: Data Table on Urinary tract infections - Market size and forecast 2022-2027 ($ million) Exhibits69: Chart on Urinary tract infections - Year-over-year growth 2022-2027 (%) Exhibits70: Data Table on Urinary tract infections - Year-over-year growth 2022-2027 (%) Exhibits71: Market opportunity by Type ($ million) Exhibits72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits73: Chart on Market share by geography 2022-2027 (%) Exhibits74: Data Table on Market share by geography 2022-2027 (%) Exhibits75: Chart on Geographic comparison Exhibits76: Data Table on Geographic comparison Exhibits77: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits78: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits79: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits80: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits81: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits82: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits83: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits84: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits85: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits86: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits87: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits88: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits93: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits94: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits95: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits96: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits97: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits98: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits99: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits100: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits101: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits102: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits103: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits104: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits105: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibits106: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibits107: Chart on France - Year-over-year growth 2022-2027 (%) Exhibits108: Data Table on France - Year-over-year growth 2022-2027 (%) Exhibits109: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits110: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits111: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits112: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits113: Market opportunity by geography ($ million) Exhibits114: Impact of drivers and challenges in 2022 and 2027 Exhibits115: Overview on Criticality of inputs and Factors of differentiation Exhibits116: Overview on factors of disruption Exhibits117: Impact of key risks on business Exhibits118: Vendors covered Exhibits119: Matrix on vendor position and classification Exhibits120: Abbott Laboratories - Overview Exhibits121: Abbott Laboratories - Business segments Exhibits122: Abbott Laboratories - Key news Exhibits123: Abbott Laboratories - Key offerings Exhibits124: Abbott Laboratories - Segment focus Exhibits125: AbbVie Inc. - Overview Exhibits126: AbbVie Inc. - Product / Service Exhibits127: AbbVie Inc. - Key news Exhibits128: AbbVie Inc. - Key offerings Exhibits129: Achilles Therapeutics plc - Overview Exhibits130: Achilles Therapeutics plc - Product / Service Exhibits131: Achilles Therapeutics plc - Key offerings Exhibits132: AstraZeneca Plc - Overview Exhibits133: AstraZeneca Plc - Product / Service Exhibits134: AstraZeneca Plc - Key news Exhibits135: AstraZeneca Plc - Key offerings Exhibits136: Bayer AG - Overview Exhibits137: Bayer AG - Business segments Exhibits138: Bayer AG - Key news Exhibits139: Bayer AG - Key offerings Exhibits140: Bayer AG - Segment focus Exhibits141: Bristol Myers Squibb Co. - Overview Exhibits142: Bristol Myers Squibb Co. - Product / Service Exhibits143: Bristol Myers Squibb Co. - Key news Exhibits144: Bristol Myers Squibb Co. - Key offerings Exhibits145: F. Hoffmann La Roche Ltd. - Overview Exhibits146: F. Hoffmann La Roche Ltd. - Business segments Exhibits147: F. Hoffmann La Roche Ltd. - Key news Exhibits148: F. Hoffmann La Roche Ltd. - Key offerings Exhibits149: F. Hoffmann La Roche Ltd. - Segment focus Exhibits150: Gilead Sciences Inc. - Overview Exhibits151: Gilead Sciences Inc. - Product / Service Exhibits152: Gilead Sciences Inc. - Key news Exhibits153: Gilead Sciences Inc. - Key offerings Exhibits154: GlaxoSmithKline Plc - Overview Exhibits155: GlaxoSmithKline Plc - Business segments Exhibits156: GlaxoSmithKline Plc - Key offerings Exhibits157: GlaxoSmithKline Plc - Segment focus Exhibits158: Johnson and Johnson - Overview Exhibits159: Johnson and Johnson - Business segments Exhibits160: Johnson and Johnson - Key news Exhibits161: Johnson and Johnson - Key offerings Exhibits162: Johnson and Johnson - Segment focus Exhibits163: Merck and Co. Inc. - Overview Exhibits164: Merck and Co. Inc. - Business segments Exhibits165: Merck and Co. Inc. - Key news Exhibits166: Merck and Co. Inc. - Key offerings Exhibits167: Merck and Co. Inc. - Segment focus Exhibits168: Novartis AG - Overview Exhibits169: Novartis AG - Business segments Exhibits170: Novartis AG - Key offerings Exhibits171: Novartis AG - Segment focus Exhibits172: Pfizer Inc. - Overview Exhibits173: Pfizer Inc. - Product / Service Exhibits174: Pfizer Inc. - Key news Exhibits175: Pfizer Inc. - Key offerings Exhibits176: Sanofi SA - Overview Exhibits177: Sanofi SA - Business segments Exhibits178: Sanofi SA - Key news Exhibits179: Sanofi SA - Key offerings Exhibits180: Sanofi SA - Segment focus Exhibits181: Viatris Inc. - Overview Exhibits182: Viatris Inc. - Business segments Exhibits183: Viatris Inc. - Key offerings Exhibits184: Viatris Inc. - Segment focus Exhibits185: Inclusions checklist Exhibits186: Exclusions checklist Exhibits187: Currency conversion rates for US$ Exhibits188: Research methodology Exhibits189: Validation techniques employed for market sizing Exhibits190: Information sources Exhibits191: List of abbreviations |
| ※참고 정보 원내 감염 치료제는 병원이나 의료기관에서 발생하는 감염증을 치료하기 위해 사용되는 약물입니다. 원내 감염은 주로 면역력이 약한 환자에서 발생하며, 병원 내에서 전파되는 병원균에 의해 발생하는 경우가 많습니다. 이러한 감염은 항생제 내성 문제로 인해 치료가 어렵고 복잡해지기 때문에 효과적인 치료제의 개발과 사용이 매우 중요합니다. 원내 감염 치료제는 대체로 항균제와 항진균제로 나눌 수 있습니다. 항균제는 세균 감염을 치료하는 데 사용되며, 주로 베타-락탐계 항생제, aminoglycoside계 항생제, 마크로라이드계 항생제 등이 포함됩니다. 특히 베타-락탐계 항생제는 다양한 종류의 세균에 효과가 있지만, 대장균, 녹농균 같은 다제내성 균주에 대해 강력한 항생제의 필요가 증가하고 있습니다. 항진균제는 진균 감염을 치료하는 데 중요한 역할을 하며, 일반적으로 아졸계, 폴리엔계, 에키노칸딘계 약물이 있습니다. 이러한 약물들은 면역력이 저하된 환자에서 발생할 수 있는 칸디다증이나 아스페르길루스 감염 등을 예방하거나 치료하는 데 사용됩니다. 원내 감염 치료제의 용도는 주로 감염의 치료뿐만 아니라 예방 치료에도 사용됩니다. 감염 위험이 높은 환자에게는 예방적인 목적으로 항생제를 투여하기도 하며, 수술 전이나 면역억제 치료를 받는 환자에게서 감염 예방을 위한 중요한 전략으로 자리 잡고 있습니다. 그러나 항생제 사용이 불필요한 내성균의 발생을 유도할 수 있기 때문에 신중한 사용이 요구됩니다. 원내 감염 치료제와 관련된 기술은 점점 발전하고 있으며, 특히 정밀의료의 인식을 통해 개인 맞춤형 치료가 가능해지고 있습니다. 이는 환자의 유전적 정보, 감염균의 특성, 그리고 항생제 내성 패턴을 기반으로 하여 최적의 치료법을 제시하는 것입니다. 바이오마커 연구와 같은 최신 기술은 감염의 조기 진단과 치료에 큰 기여를 하고 있으며, 이를 통해 보다 신속하고 정확한 치료가 가능해지고 있습니다. 또한, 연구개발에서 새로운 약물 후보 물질의 도출뿐 아니라, 기존 약물의 조합 요법도 활발히 이루어지고 있습니다. 이러한 조합 요법은 서로 다른 기전으로 작용하는 항생제를 동시에 사용하여 치료 효과를 극대화하고, 내성균의 발생을 줄이는 데 도움을 줄 수 있습니다. 이에 따라 원내 감염 치료제의 사용은 더욱 다양화되고 있으며, 새로운 연구가 이뤄지고 있어 기존 치료제와 새로운 치료제 간의 균형을 맞추는 것이 중요한 과제가 되고 있습니다. 결론적으로, 원내 감염 치료제는 병원 내의 감염 관리 및 치료에 필수적인 역할을 하며, 향후 치료제 개발 및 사용에 있어 더욱 혁신적인 접근법이 요구됩니다. 각종 기술들의 발전과 연구 결과를 통해 보다 효과적이고 안전한 치료제를 개발해 나가는 것이 우리의 과제가 될 것입니다. |
| ※본 조사보고서 [세계의 원내 감염 치료제 시장 (2023년~2027년)] (코드 : IRTNTR75007-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 원내 감염 치료제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

